Recurrent Gastrointestinal Stromal Tumours Treatment: A Comparative Study

Document Type : Original Article

Authors

The Department of General Surgery, Faculty of Medicine, Bani Swif*, Sohag** and Aswan*** Universities

Abstract

Abstract Background: In recurrent GIST whether to consider surgery or to continue on imatinib is still an open question. Aim of Study: To study the role of surgery to treat residual disease versus imatinib mesylate (IM) only to improve pro-gression free survival (PFS) and overall survival in recurrent gastrointestinal stromal tumour (GIST) patients who are responding to imatinib mesylate. Patients and Methods: Three to eight months after starting IM for recurrent GISTs, eligible patients were randomised to two groups: Group A (surgery for residual disease then IM) and Group B (IM treatment alone). In Group A (15 pts), surgery was performed to remove residual macroscopic lesions as completely as possible, and IM treatment continued after surgery. In Group B (15 pts), IM was given alone at a dose of 400mg per day until disease progression. The primary end-point was progression free survival PFS measured from the date IM started. Results: Thirty patients were enrolled in Aswan University Hospital between January 2018 to January 2021. 2-year PFS was 80% in the surgery group and 53.3% in the IM-alone group (p=0.121). Median overall survival (mOS) was 73.3% in the surgery group and 40% in patients with IM-alone group (p=0.065). Conclusions: Excision of recurrent GIST may improve the outcome of recurrent GIST patients who respond to IM.

Keywords

The Medical Journal of Cairo University
Volume 90, Issue 12
December 2022
Pages 2027-2032

Files

Share

How to cite

Statistics